News and Trends 8 Jan 2018 Bang and the Wart is Gone! Norwegian Peptide Destroys HPV-Infected Cells Cytovation has raised over €3M to finish off pre-clinical testing of its treatment for warts, and to take it into the clinic. Norwegian biotech Cytovation is developing technology for the treatment of dermatological problems, including cutaneous warts caused by human papillomavirus. It lead candidate, CyPep-H1, uses a new mechanism of action to specifically target and destroy […] January 8, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 Galapagos Teams up with Dutch Biotech to Edit Fibrosis out of our RNA Galapagos and ProQR will work together to target fibrosis using a technology to treat genetic diseases without permanent changes to the DNA. A new research collaboration between two biotech companies in Leiden, the Netherlands, will aim to discover a new class of drugs to treat fibrosis — a process of excessive scarring that leads to […] January 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 And We’re Off! First Patient Dosed in this Spanish Biotech’s Rare Disease Trial Minoryx Therapeutics has dosed the first patient in its Phase II/III trial for patients with adrenomyeloneuropathy, a condition that affects 1 in 17,000 newborns worldwide. Minoryx Therapeutics focuses on the development of new drugs for orphan diseases like adrenomyeloneuropathy. The first two patients in ADVANCE, a Phase II/III clinical trial of MIN-102, have started their treatment. The trial, […] January 8, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 Biotech in London Paves the Way for a New Therapy for Ulcerative Colitis TopiVert has successfully completed a Phase I trial in ulcerative colitis with a new class of drug that could help reduce adverse side effects. The results of a Phase I trial run by London-based biotech TopiVert have shown potential for a new type of therapy for ulcerative colitis. The study revealed that the drug, called […] January 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 This British Liquid Biopsy Could Save Us $5000 per Prostate Cancer Patient ANGLE’s liquid biopsy technology measures the expression of an important prostate cancer biomarker, helping to identify the best treatment for different groups of patients. ANGLE is a world leader in the development of liquid biopsies – a technique for the early detection of cancer, which doesn’t require invasive tissue samples. The biotech published results in […] January 8, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 This Skin Patch Could Slow the Rate of Antibiotic Resistance Researchers have developed a skin patch that delivers drugs directly into the blood, avoiding the gut which is a breeding ground for antibiotic resistance. Researchers at Queen’s University Belfast are developing a skin patch to deliver drugs through the skin and directly into the bloodstream via thousands of ‘microneedles’. The technology is being tested as a […] January 8, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2018 Takeda Starts the Year Bidding for a Belgian Stem Cell Therapy Biotech Takeda has offered to acquire TiGenix subject to the upcoming European approval of its lead stem cell therapy for Crohn’s disease, Cx601. Short of two years after partnering with TiGenix for the development of a stem cell therapy, Takeda has offered to buy the remaining shares of the company in Euronext Brussels and the Nasdaq […] January 5, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2018 Boehringer Ingelheim Doubles its Venture Fund for Exciting Biotech Boehringer Ingelheim has committed to continue helping young companies grow by doubling the size of its venture fund to €250M, which will allow it to expand its focus. Boehringer Ingelheim is a big pharma hoping to drive the development of new and effective medicines. Today, the company announced that it has more than doubled the size of […] January 4, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2018 German Biotech Raises Record $270M Series A for Individualized Cancer Therapies BioNTech will dedicate its huge fundraising to develop personalized cancer immunotherapies using CAR-T, TCR and mRNA technologies. BioNTech is kicking off the new year with great news. The company has closed its Series A with $270M (€225M) — a record amount in Germany for such an early funding round. The fundraising was led by the […] January 4, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2018 Enterome Brings in a €32M Series D for its Microbiome-Based Therapies Enterome will use the money to progress two of its leading microbiome programs for the treatment of Crohn’s disease and an aggressive form of brain cancer. Enterome is a pioneer in the exciting field of microbiome-based therapies for diseases like inflammatory bowel diseases and cancer. This morning, the company has announced that it has raised €32M in […] January 4, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2018 Swedish Biotech Pockets $6M as its Cancer Antibody Heads for the Clinic Alligator Bioscience will receive milestone payments from its partner, Janssen, following the announcement of a combination trial using its cancer antibody. Alligator develops antibodies to fight cancer, and today it has announced that it will receive $6M (€5M) in milestone payments from Janssen. This was triggered by the announcement of a combination trial for its candidate, ADC-1013, which […] January 4, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2018 Swiss Biotech Gets $339M to Boost the Development of Drug Addiction Therapies Addex Therapeutics, which develops drugs for neurological disorders, has signed an agreement with Indivior to propel its drug addiction pipeline forward. Addex, a top biotech from Geneva, develops small molecules for the treatment of neurological disorders. Today, the company has announced that a collaboration worth up to $339M (€282M) has been signed with Indivior that will focus on progressing […] January 3, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email